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Cancer survivorship has traditionally received little prioritisation and atten-
tion. For a long time, the treatment of cancer has been the main focus of
healthcare providers’ efforts. It is time to increase the amount of attention
given to patients’ long-term well-being and their ability to return to a pro-
ductive and good life. This article describes the current state of knowledge
and identifies research areas in need of development to enable interventions
for improved survivorship for all cancer patients in Europe. The article is
summed up with 11 points in need of further focus.
1. Introduction
In Europe, more than 3 million new cases of cancer
occur every year (Ferlay et al., 2013). Currently,
almost one in three individuals will develop cancer
during his or her lifetime (Jemal et al., 2011). Due to
advances in early detection, improved therapies and
supportive care, cancer survival rates have increased
substantially over the past decades (Malvezzi et al.,
2015). To date, about half of patients who are
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diagnosed with cancer will survive for 10 years or
more (Allemani et al., 2018; Cancer Research UK,
2017, De Angelis et al., 2014). The proportion of peo-
ple predicted to survive a diagnosis of cancer is
increasing by ~ 3% per year (Guzzinati et al., 2018).
An increasing prevalence of individuals with long-term
chronic health problems and comorbidity will require
a healthcare system, which can accommodate their
growing need for long-term follow-up, good quality of
life and functioning, returning to work, living indepen-
dently and a reduction of cancer recurrence.
The concept of ‘cancer survivorship’ was first articu-
lated in 1985 by Mullan in the highly influential paper
‘Seasons of Survival’. He divided cancer survivorship
into three phases: acute, extended and permanent sur-
vival (Mullan, 1985). Since then, the US institute of
medicine issued its report ‘From Cancer Patient to
Cancer Survivor – Lost in Transition’ (Insititute of
Medicine and National Research Council, 2006),
where cancer survivorship was defined to encompass
the entire cancer continuum from initial diagnosis
through the remainder of life. Cancer survivorship
often focuses on the distinct phase of cancer care that
takes place after active cancer treatment and includes
physical, mental and social aspects of living with and
after a cancer diagnosis.
Subsequently, substantial progress has been made in
survivorship research, especially in the area of immedi-
ate, persistent and late effects of cancer treatments
(Ganz et al., 2012). Many cancer patients suffer from
early or late effects of cancer and its treatment that
may cause physical and psychosocial morbidity, and
premature death (Aaronson et al., 2014; Fang et al.,
2010, 2012; Hewitt et al., 2003; Lu et al., 2013). How-
ever, along with the development of novel therapies,
new symptoms and side effects are emerging. For
example, immunotherapies have significant health and
functional impact, such as heart failure and muscu-
loskeletal dysfunction, which are not clearly defined in
clinical trials (Armenian et al., 2017; Zamorano et al.,
2016). Once new treatments have become a part of cur-
rent clinical practice, long-term follow-up of patients
receiving these treatments needs to be planned.
Translational cancer research aims to create a con-
tinuum from basic/preclinical to clinical and outcomes
research, resulting in the adoption of new diagnostic
methods and treatments. Once sufficient evidence has
been accumulated to show a reasonable balance
between the benefits and harms of established or novel
treatments, they can be incorporated into clinical
guidelines. They will then ultimately be adopted into
the current clinical practice and included in national
cancer plans.
In Europe, long-term follow-up data on the impact of
treatment on physical and psychosocial functioning or
health-related quality of life (HRQOL) are still lacking
for most cancer types. These long-term data are impor-
tant to provide a comprehensive understanding of the
outcomes of innovative diagnostics and treatments, as
well as of the quality of cancer care. Knowledge of these
outcomes is important to clinicians, healthcare policy-
makers and to patients who are cured, have no evidence
of active disease or are living with cancer as a chronic
condition. In addition, many patients want to know
what they can do themselves to improve their health
and well-being after diagnosis. Research on health beha-
viours is particularly important and timely, because the
time of a cancer diagnosis can be considered a ‘teach-
able moment’ for successful behaviour change
(Demark-Wahnefried et al., 2005; McBride et al.,
2003). Finally, many patients, when correctly cate-
gorised as ‘cured’ from their first cancer, wish to live a
normal life and not to be reminded of their past, nor be
marked with a stigma (Dumas et al., 2017).
This report describes the research areas in need of
development to enable interventions to improve qual-
ity of life and survivorship for all cancer patients in
Europe.
2. Determinants of health-related
quality of life of cancer survivors
2.1. Late effects of treatment
The development of more efficient but less toxic treat-
ments is fundamental for improving outcomes for can-
cer survivors. Despite the high cure rate achieved with
cancer surgery, some patients treated surgically suffer
from long-term side effects due to loss of organ func-
tion (Cororve Gingeret et al., 2014; Frey et al., 2014;
Gartner et al., 2010). There is a clear trend towards
the use of less invasive and burdensome surgical proce-
dures with more organ preservation as a goal (Lefeb-
vre et al., 2012; Litiere et al., 2012; Luketich et al.,
2003; Mack, 2001). Nevertheless, side effects of surgery
may negatively affect HRQOL in the long term as well
as short term (Dorval et al., 1998; Johansson et al.,
2011). When accepted as standard treatment, long-
term follow-up of patients treated with surgery can
provide valuable insights into the quality of care. This
outcome information can contribute to the develop-
ment and implementation of physical and psychosocial
rehabilitation services, and the management of side
effects and their HRQOL consequences.
Approximately 50% of all cancer patients receive
radiation therapy either with curative or palliative
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intent (Delaney et al., 2005). Radiation therapy can
cause a wide range of acute and late side effects, as
documented in more than 59 200 publications on
PubMed. Second cancers may also develop as a conse-
quence of radiation therapy (Hauptmann et al., 2016;
Teepen et al., 2018). Information on long-term side
effects and impact on HRQOL of radiation therapy is
fragmented and, for some cancers, lacking altogether
(Faithfull et al., 2015; Loos et al., 2013). Nevertheless,
technical advances in modern radiation therapy are
often aimed at providing more targeted and precise
radiation fields that spare healthy tissue, and thus
decrease side effects (Baumann et al., 2016). Long-term
follow-up of patients who have undergone radiation
therapy is required to better understand the prevalence
and nature of late radiation therapy-related side effects.
Medical oncology includes traditional chemother-
apy, hormonal treatment, targeted therapy and, more
recently, immunotherapy. Numerous acute side effects
have been documented for all medical treatment areas
reported in more than 25 900 publications on
PubMed. However, information about late side effects
is incomplete, in part because the follow-up time of
standard clinical trials is often limited. Most documen-
tation relates to traditional chemotherapy and hor-
monal treatment (Early Breast Cancer Trialists’
Collaborative Group, 2005). Targeted drugs and
immunotherapy are still in their early phase of devel-
opment. Long-term follow-up is rare and late toxicity
has still not been well documented.
It is important to emphasise that most oncological
treatments are multimodal, resulting in complex and
sometimes unanticipated long-term effects that need to
be monitored and, where possible, treated in a multi-
disciplinary manner.
Research on long-term outcomes of patients receiv-
ing anticancer treatments would ideally be based on a
complementary collaboration between clinical research
and population-based cohorts. Clinical trials which
record detailed and accurate information on treatment
provide the best data source to estimate the risks of
treatment-related side effects, for instance dose–re-
sponse of late adverse effects (Maraldo et al., 2015). In
the era of personalised medicine, long-term outcome
databases are increasingly in demand to understand
the long-term safety profile of newly approved drugs
(Kempf et al., 2017).
To assess the long-term impact of anticancer treat-
ment from the patient’s perspective, clinical researchers
need to undertake long-term follow-up studies collecting
HRQOL data from cancer survivors using question-
naires and electronic devices (van der Kaaij et al., 2010,
2012). One approach to collect such patient-reported
outcomes (PRO) would be to conduct long-term follow-
up data from patients who have participated in clinical
trials. However, re-contacting patients who were treated
many years earlier is logistically difficult and also raises
a number of medical ethical issues (e.g. informed con-
sent procedures). Additionally, trial participants may
not necessarily represent the general survivorship popu-
lation, and thus, the generalisability of the findings may
be limited. An alternative approach to collecting long-
term follow-up data from clinical trial participants is to
initiate prospective observational studies based on pop-
ulation-based cohorts that represent real-world sur-
vivors. Collaborating with population scientists and
their databases where patients are actively followed can
greatly improve the efficiency of outcomes research (Liu
et al., 2017, 2018; van de Poll-Franse et al., 2011;
Thong et al., 2017).
2.2. Health behaviours
A number of lifestyle changes can influence cancer sur-
vivors’ prognosis and well-being. Vitamin and mineral
supplement use among cancer survivors is much higher
than in the general population, despite concerns over
interference with cancer treatment (Holmes et al.,
2010; Rock et al., 2012; Velicer and Ulrich, 2008).
While the benefits of supplement use are unclear, there
are strong indications that a healthy diet, reduced
body weight, smoking cessation, increased physical
activity, use of nonsteroidal anti-inflammatory drugs
and other factors can impact prognosis and the sur-
vivorship trajectory. For example, observational stud-
ies have estimated the risk reduction of colorectal
cancer recurrence with exercise to be as high as 50%
(Loos et al., 2013). While we await the results of clini-
cal trials evaluating the effect of exercise training on
colorectal cancer prognosis, it is clear that an assess-
ment of health behaviours should be an integral part
of research studies addressing cancer survivorship.
This is also important from the patient’s perspective;
survivors want to know what they can contribute to
improve their well-being and chances of survival.
2.3. Rehabilitation
Cancer is increasingly viewed as a chronic illness, as
survivors often live for many years or decades after
their initial diagnosis and may continue to endure
physical and psychological symptoms and functional
limitations. In the context of cancer, rehabilitation has
traditionally been focused on physical functioning
impacted by physiological symptoms of cancer treat-
ment. However, there is a new conceptualisation that
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posits that cancer rehabilitation should address all the
needs of survivors, including psychological, cognitive,
social, sexual and nutritional symptoms (Burg et al.,
2015; Hunter et al., 2017). Successful survivorship can-
not be attained without rehabilitation offered as part
of comprehensive survivorship care (Liu et al., 2016).
Comprehensive survivorship and rehabilitation plans
may be valuable in supporting cancer survivors in their
return to a rewarding life. The European Commis-
sion’s Joint Action on Cancer Control issued recom-
mendations on rehabilitation and survivorship, which
have been endorsed by all 17 participating EU Mem-
ber States. The Joint Action recommends that psy-
chosocial and vocational rehabilitation should take a
person-centred approach. Empirical data on cancer
survivors’ risk profiles in terms of health status,
comorbidity, health-related costs and mortality are a
prerequisite to organising survivorship plans, and
specifically tailored activities for health promotion and
health care. Thus, large-scale and nationwide data col-
lection is warranted [‘Innovative Partnership for
Action Against Cancer (iPAAC) and European cancer
information system’ (https://ecis.jrc.ec.europa.eu)].
The recently published ‘Patient Guide on Survivor-
ship’ (https://www.esmo.org/Patients/Patient-Guides/
Patient-Guide-on-Survivorship) includes a section on
cancer rehabilitation and timely detection, management
and treatment of tumour-related symptoms, as well as
the use of a survivorship care plan that people with can-
cer can use in collaboration with their healthcare team
to facilitate a return to normal life. Survivorship care
plans are often highly appreciated by the patients, but
because there is little empirical data that supports the
efficacy of survivorship care plans, additional research
to assess their possible benefits is urgently needed.
Comprehensive rehabilitation is a multidisciplinary
concern. A new cancer care and survivorship model
that integrates all multidisciplinary areas into one
rehabilitation team must be established. Policy efforts
are also needed to actively engage patient advocacy
groups to support equal access to quality survivorship
care and rehabilitation services. Involving patients in
the follow-up and management of late effects or the
rehabilitation process is a major challenge. Online pro-
grammes and e-health may be a good alternative for
educating survivors, since these tools are considered
cost-efficient and show a similar impact to more con-
ventional interventions.
2.4. Physical and functional fitness
Cancer-related fatigue is one of the most common
complaints of cancer patients. Fatigue often becomes
chronic, extending for years into the cancer survivor-
ship period (Daniels et al., 2014; Jones et al., 2016;
Weis et al., 2017). It can also be a key limitation in a
patient’s ability to return to a productive work life. A
large number of studies (including sizeable clinical tri-
als) have shown that exercise can play an important
and effective role in reducing this debilitating condi-
tion (Cheng et al., 2017; Cramer et al., 2017; Cramp
and Byron-Daniel, 2012). The benefits of exercise have
been described for a multitude of cancer types (Sch-
mitz et al., 2010) and appear to be most prominent
among patients with an initially low performance sta-
tus (Troeschel et al., 2018). Research in this area con-
tinues to evaluate the most effective exercise regimens,
including the impact of resistance versus endurance
training, and the timing in relation to surgery and
therapy.
2.5. Psychosocial care
Between 30% and 50% of cancer survivors may experi-
ence psychological distress significant enough to war-
rant professional intervention sometime during the
survivorship period (Mitchell et al., 2011). Historically,
psychosocial support has been neglected in cancer
treatment (Holland and Reznik, 2005). Today however,
several organisations strongly recommend the inclusion
of psychosocial care across the continuum of treat-
ment, from diagnosis, through treatment into survivor-
ship and palliative stages of care (Associazione Italiana
di Oncologia Medica and Caminiti, 2013, Jacobsen,
2009, National Breast Cancer Center and National
Cancer Control Initiative, 2003; National Institutet for
Clinical Excellence, 2004, Skolarus et al., 2014).
Screening for psychological distress at the time of diag-
nosis is used to identify patients with needs in a timely
manner (Jacobsen et al., 2005). Still, research about
psychological distress in cancer survivors is a relatively
unexplored area (Jacobsen, 2009). The impact of psy-
chosocial care and support at diagnosis and during
treatment on long-term HRQOL is poorly understood.
To help empower patients, increasing attention is
devoted to facilitating shared decision-making (Barry
and Edgman-Levitan, 2012; Makoul and Clayman,
2006). There is a need for open and affirming patient–
clinician dialogue about the illness and its treatment
options (Ramfelt and Lutzen, 2005; Thorne et al.,
2013). Studies have shown that the information
exchange between clinicians and cancer patients is
often suboptimal (Hawley and Jagsi, 2015; Kullberg
et al., 2015). Little is known about the effects of
patient involvement in cancer treatment decision-mak-
ing on long-term health and psychosocial outcomes.
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2.6. Palliative care
Palliative care aims to control physical, medical and
functional symptoms, psychological and emotional
problems, social, existential and spiritual needs. It is
intended to be personalised; using a spectrum of treat-
ments such as isolation, altered social relationships,
socio-economic challenges and assistance with decision-
making around end of life issues (Ferrell et al., 2017).
Palliative care is particularly relevant for improving
patients’ HRQOL, their ability to remain in the home,
and avoidance of over-treatment. Palliative care has
two components; early palliative care regimens should
start when cure is no longer possible but with the inten-
tion of prolonging survival. Late palliative care starts
when prolongation of survival is no longer possible
and is focused primarily on symptom relief. Today,
increasing numbers of patients with advanced cancer
can live for a relatively long time, and the disease may
even be viewed as chronic (Phillips and Currow, 2010).
However, palliative care has traditionally been deliv-
ered late in the course of the disease (late palliative
care) to patients who are hospitalised in specialised
inpatient units or as a consultative service for patients
with uncontrolled symptoms (Jordhoy et al., 2001). To
have a meaningful effect on patients’ HRQOL and on
end of life care, palliative care services should be well
planned and provided earlier in the course of the dis-
ease (Temel et al., 2010). The nature and organisation
of palliative care vary widely across settings, and there
is insufficient evidence regarding which programmes
and interventions are optimal for relieving symptoms
and for maintaining, if not improving, HRQOL.
2.7. How should survivorship care be organised
in Europe?
Europe has no formalised indications on how survivor-
ship care should be organised. There are many recom-
mendations and policy efforts, but no generic practical
approach has been established. The challenge is to
decide how survivorship care should be organised in
Europe, whether in specialised survivorship clinics as
in the United States, in rehabilitation clinics as in Ger-
many, or according to an entirely different approach.
Between the European countries, there are large differ-
ences in healthcare systems and culture in relation to
health care and health behaviour. These differences
might make a European-wide approach feasible. Per-
haps some basic features of survivorship care should
be shared across countries within Europe, but each
country needs to develop approaches to cancer sur-
vivorship care that reflect its own healthcare system
and cultural norms. However, all European Union citi-
zens should have equal access to optimal survivorship
care (Lawler et al., 2014).
In the United States, specialised multidisciplinary
hospital services, sometimes referred to as Survivorship
Clinics, address various aspects of survivorship care.
The multidisciplinary teams at these facilities may
include a wide range of providers such as physicians,
nurses, dieticians, mental health professionals, social
workers, physiotherapists and rehabilitation specialists.
Many cancer survivors, particularly those who are rel-
atively asymptomatic or who are considered disease-
free, will likely be seen in the primary care setting by
general practitioners. Thus, general practitioners will
need to be integrated as an essential part of high-qual-
ity multidisciplinary cancer survivorship care, as men-
tioned in the Joint Action on Cancer Control’s Work
Package 8 recommendations.
In light of the ever-growing population of cancer
survivors, it is important to recognise the need to
avoid overpopulating the cancer care clinics, where the
emphasis is on providing primary and palliative treat-
ment. If survivors are to be seen in primary care set-
tings, general practitioners need to be provided with
adequate training and resources to understand and
manage their unique long-term care needs. Addition-
ally, general practitioners need to be aware of the risks
associated with being a cancer survivor, such as a wide
range of comorbid conditions including second can-
cers, and deficits in functional, emotional, social and
spiritual health. Specifically, healthcare providers need
training and resources to identify, screen and manage
long-term, late effects such as early-onset cardiovascu-
lar disease, osteoporosis and other organ dysfunctions.
The American Cancer Society and the George
Washington Cancer Institute, with support from the
centers from disease control, have collaborated to
develop a series of e-learning cancer survivorship mod-
ules aimed directly at educating general practitioners
about important cancer survivorship issues. These
efforts, along with the emergence of cancer rehabilita-
tion as a focus of comprehensive care for survivors,
underscore the need for additional research and policy
efforts to understand how best to care for the growing
population of European cancer survivors. By expand-
ing current research capacity with increasing pan-Eur-
opean funding, these objectives can be achieved. For
example, cancer registries are increasingly being used
to collect data on survivors, which may help produce
stronger epidemiological evidence, including informa-
tion on lifestyle factors, HRQOL and socio-economic
indicators to better identify the causes of, for example,
inequalities in survivorship.
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As recommended in the chapter on Survivorship and
Rehabilitation of the European Commission Joint
Action on Cancer Control’s Guide (Albreht et al., 2017),
cancer registries should begin to collect data on other fac-
tors that impact quality of life, such as rehabilitation and
capacity to return to work after the completion of treat-
ment. Systems are needed for the surveillance of long-
term and late effects of cancer treatment (physical, psy-
chological, cognitive, social and sexual functions).
In addition to objective measures of such symptoms,
there is a need for increased inclusion of PROs in routine
clinical practice and in research in order to identify the
issues that are most important to survivors and their
loved ones. Advances in the development, implementa-
tion and evaluation of survivorship care, including
comprehensive rehabilitation services, are also needed.
Specifically, rehabilitation services need to focus on help-
ing survivors achieve healthy lifestyles to improve self-
management of symptoms and long-term health. Health-
care providers need to be offered continued training
around a wide range of survivorship care issues including
screening for psychosocial distress, surveillance for recur-
rence and second cancers, assessment and management
of long-term late effects, communication and supportive
care skills, and appropriate referral to specialised provi-
ders. Integration of e-health solutions will improve the
diffusion of interventions, particularly to those within
rural areas or with limitations to their ability to utilise
traditional medical care settings.
3. Structuring future cancer
survivorship research
Cancer survivorship includes a broad range of issues
and challenges. Major areas of need have been outlined
in anticipation of the development of a comprehensive
research agenda for European cancer survivors. Close
interaction between behavioural scientists, epidemiolo-
gists, clinical investigators, and media and computer
scientists is needed to fully leverage the existing
resources and identify the need for others. Although
the predominant factors are the diagnostic stigma, the
short-term and long-term side effects of treatment, the
course of the disease and the psychosocial environ-
ment, many other personal and societal factors are at
play, such as comorbidity, stress reaction, socio-eco-
nomic status and access to the healthcare system.
3.1. HRQOL – a fundamental issue for cancer
survivors
Patient-reported outcomes are becoming central to the
understanding of cancer survivorship, clinical outcomes
and patient needs. HRQOL is multifaceted and linked to
a number of factors, including the disease (and its symp-
toms) and the treatment (and its side effects) (Aaronson,
1988). Important dimensions of PROs include anxiety,
depression, distress and self-efficacy, among others.
Increasingly, methods to assess HRQOL and other PROs
are being incorporated as a standard part of clinical trials
and comparative effectiveness studies (US Department of
Health, Human Services Health, 2006). A number of
well-validated HRQOL measures have proven useful
both in clinical research and clinical practice settings.
These include, among others, the European Organisation
for Research and Treatment of Cancer (EORTC) portfo-
lio of measures (the core QLQ-C30 questionnaire and its
many condition-specific or treatment-specific modules)
(Aaronson et al., 1993), and the Functional Assessment
of Cancer Therapy suite of measures (Cella et al., 1993).
More recently, both the United States National
Institute of Health (the PROMIS initiative) and the
EORTC (the computer adaptive technology initiative)
have developed computer-adaptive approaches to
PRO measures that facilitate rapid, efficient and accu-
rate real-time assessment of HRQOL and other rele-
vant outcomes in the era of personalised medicine
(Cella et al., 2007, 2010; Petersen et al., 2018). Sev-
eral instruments, most notably the Impact of Cancer
questionnaire (Zebrack et al., 2006), aim to address a
range of physical and psychosocial survivorship
issues. The EORTC Quality of Life Group is cur-
rently carrying out a project to adapt its HRQOL
measures to the survivorship setting (van Leeuwen
et al., 2018). Development of new computer-adaptive
approaches and applications for smartphones facili-
tates HRQOL assessment in a cost-effective manner
with greater precision. It also allows a much timelier
and detailed monitoring of treatment side effects,
mental status, need for palliation and other support-
ive care needs (Basch et al., 2017), as well as more
direct advice and answers to questions via such com-
munication.
3.2. Comprehensive cancer centre for improved
cancer survivorship
The comprehensive cancer centre (CCC) is today the
optimal organisation for therapy development and
delivery of high-quality cancer care; an organisation
where cancer care is integrated with research and edu-
cation. Multidisciplinary research activities should
include supportive care, psychosocial oncology, reha-
bilitation and outcomes research. Long-term follow-up
of patients should be a mandatory mission of the
CCCs. In order to reach the critical mass for
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comprehensive cancer survivorship research, CCCs
should interact in a network to optimise exchange and
harmonisation of approaches. Systematic and stan-
dardised collection of clinical information and
biobanking, including long-term follow-up of PROs,
will facilitate translational cancer research aimed at
improving cancer survivorship. This is a critical and
complex issue when approaching personalised cancer
medicine with possibilities to predict both antitumour
effects and side effects.
3.3. Science policy is needed for improved cancer
survivorship
The current paper has revealed three salient features of
science policy needs for improved cancer survivorship.
First, cancer survivorship has traditionally received little
prioritisation and attention. Treatment of the cancer –
with surgery, radiation therapy and medical anticancer
agents – has been the main focus of our efforts as
healthcare providers. It is time to increase the amount
of attention given to patients’ long-term well-being and
their ability to return to a productive and good life. Sec-
ond, relatively little is known about the differences in
approaches to cancer survivorship across European
countries. Even less is understood about how differences
in health care during the survivorship phase are influ-
enced by age, socio-economic status, ethnicity, urban
versus rural residence and possibly other factors. Third,
the area of cancer survivorship research needs greater
attention and acknowledgement in the scientific litera-
ture. The emergence of journals such as the Journal of
Cancer Survivorship, recent survivorship conferences,
the iPAAC actions, and e-learning and collaborative
research initiatives such as that of the EORTC for the
development of new survivorship measures are indica-
tors of an increasing interest in the topic of survivorship.
Compared to all other areas of cancer research, the pub-
lication of high-quality research on cancer survivorship
is sparse, although increasing. This lack is associated
with the scarce resources allocated by national or inter-
national bodies for observational studies on cancer sur-
vivorship. In fact, much less funding and fewer calls are
dedicated to observational clinical studies, compared to
experimental studies or basic research. A dedicated
framework for these issues by the EU will contribute to
fulfilling the needs of a vastly growing population of
cancer survivors (Albreht et al., 2017).
We believe that the time is ripe for a European initia-
tive to improve cancer survivorship and HRQOL among
the millions of individuals who live as cancer survivors.
As already indicated, the number of survivors is expected
to rise substantially over time due to demographic transi-
tion, increasing incidence of some cancers and more suc-
cessful treatments that will increase cure rates and extend
life expectancy. A pan-European initiative requires two
components: a comprehensive research agenda that ulti-
mately provides the evidence base for cost-effective, indi-
vidualised management of cancer survivors; and the
political will to invest in a healthcare system with
resources to support cancer patients beyond the phase of
primary treatment and throughout their lives.
Europe might indeed have a competitive advantage in
pursuing high-quality research on cancer survivorship
because it can build on existing collaborative structures,
geographic proximity, initial models (e.g. the rehabilita-
tion system in Germany) and, in some countries, an
infrastructure that facilitates complete long-term fol-
low-up of individuals. Examples include the population
registries in Scandinavia and cancer registries with
PROs in the Netherlands and in Germany. These pre-
requisites are lacking in most other parts of the world.
For a comprehensive cancer survivorship research pro-
gramme, international collaboration is required. Fund-
ing support at the European level is necessary to set
cancer survivorship research priorities as well as to
develop and implement research programmes.
With this background in mind, the following focus
points are proposed:
 Outcomes research with a focus on cancer sur-
vivorship should be a component of the transla-
tional cancer research continuum and integrated
in all CCCs.
 Long-term follow-up of patients should be a tar-
get of centres involved in therapy development.
This would create the linkage between detailed
treatment data and issues such as HRQOL and
long-term health risks of cancer survivors and
may serve as a structure for translational research
to limit side effects and improve HRQOL.
 Because the cure rate among paediatric oncology
patients is high, the prevalence of long-term sur-
vivors is growing and long-term HRQOL issues are
increasingly important. The pan-European network
for survivors after childhood and adolescent cancer
may be a model for adult cancer survivors.
 A CCC has an important role in researching the
long-term follow-up of patients with a focus on out-
comes research and innovations. As not all patients
are treated in a CCC, research should ideally be
built on a collaborative partnership involving other
key stakeholders to establish a robust methodology
and achieve optimal external validity. Stakeholders
include patient organisations, healthcare providers,
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clinical research organisations and those with data
based on real-world observational cohorts. Fur-
thermore, involvement of payers and Health Tech-
nology Assessment bodies will facilitate the
implementation of research findings.
 The CCC accreditation methodologies should
include analyses of research on HRQOL, long-
term (treatment-related) adverse effects, support-
ive care, psychosocial oncology and rehabilita-
tion interventions.
 The assessment of health behaviours, such as
exercise, tobacco smoking, use of vitamin and
mineral supplements, and diet is integral to a
comprehensive evaluation of factors relevant to
cancer prognosis and patient HRQOL.
 Collaboration between CCCs is required to
develop and validate instruments harmonised
across European countries to assess HRQOL
among cancer survivors.
 Funding mechanisms for international collabora-
tions in the area of cancer survivorship research are
currently lacking. With the growing population of
cancer survivors, the rapid development of new
diagnostic and treatment methods and the lack of
information regarding HRQOL of surviving cancer
patients, identification of priorities and funding
mechanisms are important science policy questions
that need to be addressed. A funding mechanism
that aims to investigate and improve cancer sur-
vivorship should have an emphasis on Europe, in
addition to the existing national perspective, with
high-level competence to review grant applications
and to fund cutting-edge research.
 In order to better reflect real-world conditions,
survivorship, effectiveness of treatments and can-
cer outcomes should be investigated not only in
controlled clinical trial settings, but also through
clinical and population-based observational stud-
ies with long-term follow-up of unselected groups
of patients.
 A further technical development in the collection
of PROs is warranted, including computer-adap-
tive approaches and applications for smart-
phones, and collaboration with the computer
science experts should expand in order to take
advantage of the Big Data revolution (Mayer-
Sch€onberger and Cukier, 2013).
 Finally, societal issues, such as access to work, edu-
cation, insurance, loan, mortgage and financial tox-
icity, faced by long-term cancer survivors should be
evaluated and prioritised in the survivorship
research agenda. It is critical to communicate that
for a majority of cancer patients in Europe, cancer
is not a death sentence, and the social sector should
play a complementary role to the health sector in
improving reintegration of survivors to normal
social roles and activities without discrimination.
Collaborative platforms, such as the EORTC Can-
cer Survivorship Research Program, Your Outcome
Update research protocol, EORTC Cancer Sur-
vivorship Summits and the European Cancer
Patient Coalition Congress, are crucial to increase
such awareness and to foster efficient research in
this issue (Liu et al., 2016, 2018).
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